Intensive Care Medicine publishes the results of Inotrem’s study which demonstrated the safety and tolerability of its lead compound, nangibotide, in patients suffering from septic shock.
Paris (France). June 2nd. 2020. Inotrem S.A., a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, through its knowledge of the TREM-1 pathway biology, announced today that peer review journal Intensive Care Medicine has published the results of its Phase IIa study which demonstrated the safety and tolerability of its lead compound in patients suffering from septic shock…